权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Genome Targeted Inhibitors of Retroviruses

逆转录病毒基因组靶向抑制剂

基本信息

批准号：
7173294
负责人：
Virendra Nath PANDEY
金额：
$ 36.86万
依托单位：
UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
起止时间：
1999-04-01 至 2009-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7173294
关键词：
Animal Model Anti-HIV Agents Antiviral Agents Appendix Cell Proliferation Cells Child Class Clinical Conserved Sequence Cultured Cells Data Development Plans Dimerization Drug Delivery Systems Drug Formulations Drug Kinetics Drug or chemical Tissue Distribution Drug resistance Drug usage Evaluation Exhibits Face Fluorescein Fluoresceins Gagging Genetic Genome HIV-1 Human Immune response In Vitro Individual Kinetics Life Cycle Stages Literature Lymphoid Cell Manuscripts Measures Membrane Methods Minority Monitor Mus Numbers Nylons Peptides Peripheral Blood Lymphocyte Peripheral Blood Mononuclear Cell Phase Pliability Progress Reports Property Publications RNA Regulatory Element Reporter Genes Research Research Design Resort Resources Retroviridae Reverse Transcription SCID Mice SCID-hu Mice Safety Staging Tars Therapeutic Therapeutic Index Translations Vertebrates Viral Viral Genome Virus Virus Diseases Woman cytokine cytotoxicity design fluorophore genome sequencing human subject in vivo inhibitor/antagonist mouse model novel nucleotide analog pol genes prevent reconstitution response uptake vector

项目摘要

four pages) ............. 6-8 Other Biographical Sketches (Not to exceed four pages for each) ............................................... 9-31 Resources ...................................................................................................................................... 32 Research Plan 33-35 Introductionto Revised Application (Not to exceed 3 pages) ............................................................................................................................... Introduction to Supplemental Application (Notto exceed one page) .................................................................................................................... A. Specific Aims .......................................................................... _ ......................................................................................................... 36-60 B. Background and Significance ...................................................... !...................................................................................................... _._" C. Preliminary Studies/Progress Report/ _ (Items A-D: not to exceed 25 pages*) _K_ Phase I Progress Report (SBIPJSTTR Phase II ONLY) I * SBIR/STTR Phase I: Items A-D limited to 15 pages, t D. Research Design and Methods ............................................ _ ..................................................................................................... E Human Subjects ......................................................................................................................................................................................... Protection of Human Subjects (Required if Item 4 on the Face Page is marked "Yes") Inclusion of Women (Required if Item 4 on the Face Page is marked "Yes") ................................................................................... Inclusion of Minorities (Required if Item 4 on the Face Page is marked "Yes") ................................................................................ Inclusion of Children (Required if Item 4 on the Face Page is marked "Yes") ................................................................................... Data and Safety Monitoring Plan (Required if Item 4 on the Face Page is marked "Yes" anda Phase I, 11,or III clinical roposed trial is proposed ................................................................................................................................................................................ F. Vertebrate Animals ..................................................................................................................................................................................... 61 G, Literature Cited ........................................................................................................................................................................................... H. Consortium/Contractual Arrangements .................................................................................................................................................... I. Consultants ................................................................................................................................................................................................. 68-74 J. Product Development Plan (SBIR/STTR Phase I1and Fast-Track ONLY) ........................................................................................... Checklist ........................................................................................................................................ 75 Check if Appendix (Five collated sets_ No page numbering necessary for Appendix.) Appendix is Included Appendices NOT PERMITTED for Phase I SBIR/S TTR unless specifically solicited, 6 Number of publications and manuscripts accepted for publication (not to exceed 10) Other items (list): PHS 398 (Rev, 510 l) Page 3 Number pages consecutively at the bottom throughout the application. Do _t use suffixes such as 3a, 3b,

四页）. 6-8 其他个人简介（每份不超过四页）... 9-31 资源...... 32 研究计划 33-35 经修订的申请简介（不超过3页）..... 补充申请简介（不超过一页）.... A.具体目标...... _ ......................................................................................................... 36-60 B。背景及意义.... !...................................................................................................... _._ " C.初步研究/进度报告/ _（项目A-D：不超过25页 *）_K_ 第I阶段进度报告（仅限SBIPJSTTR第II阶段）I * SBIR/STTR第I阶段：项目A-D限于15页， D.研究设计和方法........ _ ..................................................................................................... E人类受试者......................................................................................................................................................................................... 人类受试者保护（如果正面页面上的第4项标记为“是”，则需要）纳入女性（如果正面页面上的项目4标记为“是”，则需要）... 纳入少数群体（如果正面页项目4标记为“是”，则需要）.... 包括儿童（如果正面页上的第4项标记为“是”，则需要）..... 数据和安全性监测计划（如果正面页面上的第4项标记为“是”，则需要，并且I、11或III期临床试验建议试用................................................................................................................................................................................ F.脊椎动物..................................................................................................................................................................................... 61 G、引用的文献........................................................................................................................................................................................... H.联合会/合同安排.................................................................................................................................................... I.顾问................................................................................................................................................................................................. 68-74 J.产品开发计划（仅限SBIR/STTR阶段I1和快速通道）....... 核对表.. 75 检查是否附录（五个整理集_附录无需页码。）阑尾是包括附录不允许用于I期SBIR/S TTR，除非特别要求， 6 接受出版的出版物和手稿数量（不超过10份）其他项目（列表）： PHS 398（修订版，510 l）第3页在整个应用程序的底部连续编号页面。不要使用后缀，如3a，3b，

项目成果

期刊论文数量（17）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

A peptide nucleic acid-neamine conjugate that targets and cleaves HIV-1 TAR RNA inhibits viral replication.

靶向并切割 HIV-1 TAR RNA 的肽核酸-新胺缀合物可抑制病毒复制。

DOI：
10.1021/jm049642d
发表时间：
2004
期刊：
Journal of medicinal chemistry
影响因子：
7.3
作者：
Riguet,Emmanuel;Tripathi,Snehlata;Chaubey,Binay;Desire,Jerome;Pandey,VirendraN;Decout,Jean-Luc
通讯作者：
Decout,Jean-Luc

Inhibition of HIV Replication by Cyclic and Hairpin PNAs Targeting the HIV-1 TAR RNA Loop.

DOI：
10.1155/2012/591025
发表时间：
2012
期刊：
Journal of nucleic acids
影响因子：
2.3
作者：
Upert G;Di Giorgio A;Upadhyay A;Manvar D;Pandey N;Pandey VN;Patino N
通讯作者：
Patino N

Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides.

DOI：
10.1093/nar/gki743
发表时间：
2005
期刊：
Nucleic acids research
影响因子：
14.9
作者：
Tripathi S;Chaubey B;Ganguly S;Harris D;Casale RA;Pandey VN
通讯作者：
Pandey VN

A single deletion at position 134, 135, or 136 in the beta 7-beta 8 loop of the p51 subunit of HIV-1 RT disrupts the formation of heterodimeric enzyme.

HIV-1 RT p51 亚基的 β7-β8 环中第 134、135 或 136 位的单个缺失会破坏异二聚酶的形成。

DOI：
10.1002/jcb.22439
发表时间：
2010
期刊：
Journal of cellular biochemistry
影响因子：
4
作者：
Upadhyay,Alok;Pandey,Nootan;Mishra,ChaturbhujA;Talele,TanajiT;Pandey,VirendraN
通讯作者：
Pandey,VirendraN

Immunological response to peptide nucleic acid and its peptide conjugate targeted to transactivation response (TAR) region of HIV-1 RNA genome.

针对 HIV-1 RNA 基因组反式激活反应 (TAR) 区域的肽核酸及其肽缀合物的免疫反应。